May 1 | News
April proved to be a big month for M&A activity as companies announced more than $29 billion in agreed upon transactions during the month, the bulk of which occurred during the final week.
|
Apr 25 | News
AstraZeneca and The Medicines Company announced today a global collaboration for acute ischemic heart disease compounds. The first part of this collaboration is a US co-promotion for AstraZeneca's oral antiplatelet medicine BRILINTA(R) (ticagrelor) tablets.
|
Apr 23 | News
LONDON (AP) — Anglo-Swedish drug company AstraZeneca PLC is buying Ardea Biosciences, Inc., in a deal which values the U.S. biotech company at $1.26 billion.
|
Apr 16 | News
Conformetrix Ltd, a drug discovery and design company, and AstraZeneca announced today that they have signed a research collaboration agreement under which Conformetrix's proprietary NMR-based technology will be applied across AstraZeneca's pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.
|
Apr 13 | News
NEW YORK (AP) — AstraZeneca PLC said Thursday that it is now selling the new blood pressure medication Dutoprol, and the British drugmaker said it plans to ship the drug directly to patients.
|
Apr 10 | News
Some of AstraZeneca’s largest investors are lobbying to replace CEO David Brennan and other members of the board and executive team and usher in a new business strategy.
|
Mar 22 | News
LONDON (AP) — AstraZeneca PLC says that a British court has ruled that its patent on antidepressant drug Seroquel, XR is invalid.
|
Mar 13 | News
AstraZeneca announced Tuesday that the company filed a lawsuit against the FDA seeking to overturn the agency's recent decision rejecting two Citizen Petitions for Seroquel (quetiapine).
|
Mar 12 | News
WASHINGTON (AP) — AstraZeneca said Friday the FDA rejected a request that would have delayed the launch of generic versions of the company's blockbuster psychiatric drug Seroquel.
|
Feb 3 | News
MONTREAL — Montreal's pharmaceutical research cluster is under further threat as global giants adjust to the loss of patent protection for blockbuster drugs and challenges in developing replacements.
|